Open original FDA record ↗Recall record
- FDA identifier
- Z-0460-2022
- Company in FDA record
- Abbott Molecular, Inc.
- FDA record creation date
- Jan 6, 2022
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
There is a potential for abnormal (non-sigmoidal) amplification curves.
Source facts
- Action
- On December 06, 2021 Abbott Molecular issued a Product Correction letter to all customers who received an Alinity m instrument (List Number 08N53 002). Customers are instructed to follow the Necessary Actions outlined in the Customer Letter until an Abbott Molecular representative adjusts the customers clamp bar. Abbott personnel will follow up with customers by e mailing and or follow up visits/phone calls.
- Initiated
- 2021-12-06
- Root cause
- Under Investigation by firm
- Distribution
- Worldwide distribution - US Nationwide and the countries of Australia, Austria, Belgium, Brazil, Cambodia, Canada, Chile, Colombia, Czech Republic, Egypt, El Salvador, Estonia, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Malawi, Malaysia, Mexico, Montenegro, Morocco, Mozambique, Netherlands, New Zealand, Norway, Pakistan, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Uganda, United Kingdom, and Vietnam.
- Recall number
- Z-0460-2022
- Recall status
- Open, Classified
- CDRH record ID
- 190678
- FDA record created
- 2022-01-06
- Recall event number
- 89166